Evidence map›Paper›PMID 33688650›Full record

ArticlebioRxiv : the preprint server for biology2021

Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice.

James Brett Case, Rita E Chen, Longxing Cao, Baoling Ying, Emma S Winkler, Inna Goreshnik, Swathi Shrihari, Natasha M Kafai, Adam L Bailey, Xuping Xie and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

James Brett CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Rita E ChenDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Longxing CaoDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Baoling YingDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Emma S WinklerDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Inna GoreshnikDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Swathi ShrihariDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Natasha M KafaiDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Adam L BaileyDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, USA.
Rashmi RavichandranDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Lauren CarterDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Lance StewartDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
David BakerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Washington University in St. Louis · USUniversity of Washington · USThe University of Texas Medical Branch at Galveston · USHoward Hughes Medical Institute · US

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
Infectious Diseases/Basic Microbial Pathogenic MechanismsT32AI007172 · NIAID · WASHINGTON UNIVERSITY · PI Daniel E. Goldberg, JENNIFER A PHILIPS · 1985 to 2026
$13.0M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
Regulation of Antiviral Responses in Plasmacytoid Dendritic Cells to Chikungunya Virus by the Gut MicrobiotaF30AI152327 · NIAID · WASHINGTON UNIVERSITY · PI WINKLER, EMMA SUENING · 2021 to 2022
$84k
NCATS NIH HHS UL1 TR001439NIAID NIH HHS F30 AI152327NIAID NIH HHS R01 AI157155NIAID NIH HHS T32 AI007172
6 · The paper itself

Abstract

Despite the introduction of public health measures and spike protein-based vaccines to mitigate the COVID-19 pandemic, SARS-CoV-2 infections and deaths continue to rise. Previously, we used a structural design approach to develop picomolar range miniproteins targeting the SARS-CoV-2 receptor binding domain. Here, we investigated the capacity of modified versions of one lead binder, LCB1, to protect against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice. Systemic administration of LCB1-Fc reduced viral burden, diminished immune cell infiltration and inflammation, and completely prevented lung disease and pathology. A single intranasal dose of LCB1v1.3 reduced SARS-CoV-2 infection in the lung even when given as many as five days before or two days after virus inoculation. Importantly, LCB1v1.3 protected

Identifiers

PMID33688650
PMCPMC7941621
OpenAlexW3133528634

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.